The group leader said that they have detected low concentrations of human thyroid-stimulating hormone as a demonstration of the platform's broader capabilities.
Its tests use FTIR to measure the spectra from biochemical changes in peripheral blood mononuclear cells, along with a proprietary technique that analyzes results.
The test, which could be available to clinicians within a year as a lab-developed test, could elevate saliva as a more popular sample medium.
The group said that progress in developing the test for a broad range of medical conditions will be driven in part by frequent donations of urine samples.
In a study, the researchers used patients' blood plasma and infrared spectroscopy to diagnose dementias, and differentiate different forms of the condition from each other.
Laboratories are developing mitigation strategies to raise awareness that biotin supplements may be interfering with some patient test results.
The present prototype is being expanded to use five liver cancer markers instead of one, and the researchers are developing it to detect other diseases.
Along with a change in guidelines, a number of payors have stopped paying for blood-based H. pylori testing, possibly heralding an uptick in sales for Exalenz's test.
During a clinical study, a positive antimicrobial stewardship outcome emerged in 74 percent of cases where the firm's test provided a rule-out result for sepsis.
The firm recently announced that it is developing a new range of clinical flow systems that it expects to launch over the next five years.